Trinity Biotech plc (TRIB)

DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director.

Approval Facilitates Immediate Offshored and Outsourced Manufacturing Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity's Broader Profitability and Growth Objectives DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the in-country healthcare product regulatory authority has granted the key approval to initiate offshore and outsourced manufacturing of its flagship World Health Organization (WHO) prequalified TrinScreen™ HIV rapid test. This key approval now enables Trinity Biotech to transition upstream production from its legacy in-house operations to a more cost-effective and scalable outsourced model, while maintaining the highest levels of product integrity and regulatory compliance.

TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.

New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of pregnancy New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of pregnancy

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company's next-generation CGM+ biosensor platform

FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a significant advancement in maternal health diagnostics. The service is planned to be rolled out in Q3 2025 through Trinity Biotech's New York-based reference laboratory.

WILSONVILLE, Ore. and DUBLIN, July 24, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity's new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.

-Trinity Biotech projects it reached Adjusted EBITDA 1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA 1 positive going forward, reflecting continued strong execution on its comprehensive transformation plan.-

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended.

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares (“ADSs”) for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days.

DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan.

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors.

Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029

Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029

DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.